The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children’s Oncology Group.
 
Pooja Hingorani
No Relationships to Disclose
 
Mark D. Krailo
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Allen Buxton
No Relationships to Disclose
 
Paul R. Hutson
No Relationships to Disclose
 
Justin Davis
No Relationships to Disclose
 
Katherine A. Janeway
Consulting or Advisory Role - Bayer
Patents, Royalties, Other Intellectual Property - Amgen (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer
 
Richard Greg Gorlick
Research Funding - Eisai (Inst)
 
Michael Isakoff
No Relationships to Disclose